UPDATE - Issue 32 - Winter 2008
New BPH drug
The young Scottish company Ardana, set up to exploit research from the Edinburgh based Human Reproductive Science Unit, seems to be making progress with its drug Teverelix. The results from its phase II study suggest that the drug works well to treat the symptoms of Benign Prostatic Hyperplasia. The attraction of the drug is that patients would only need two maintenance doses per year. Before it reaches the market, however, the lengthy and expensive process of a Phase III trial must be gone through.